Information Provided By: 
Fly News Breaks for January 25, 2017
JAZZ
Jan 25, 2017 | 07:56 EDT
UBS analyst Marc Goodman noted Jazz Pharmaceuticals' supplier received an FDA Warning Letter with regards to observations made by the FDA during its inspection of Porton Biopharma's manufacturing facility that makes Erwinase for Jazz. The analyst does not believe production will stop as they believe the FDA will work with the company to resolve the issues. Goodman said Jazz Pharmaceuticals remains his favorite mid-cap name for 2017 and reiterated his Buy rating and $168 price target.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
